# A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis

> **NCT06149520** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 258 (actual)

## Conditions studied

- Thrombolysis
- Symptomatic Proximal Deep Vein Thrombosis

## Interventions

- **DRUG:** BAY3018250
- **DRUG:** Placebo to BAY3018250

## Key facts

- **NCT ID:** NCT06149520
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-15
- **Primary completion:** 2025-10-07
- **Final completion:** 2025-12-02
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06149520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06149520, "A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06149520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*